Journal
MATURITAS
Volume 75, Issue 4, Pages 392-396Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.maturitas.2013.05.013
Keywords
Osteoporosis; Fracture; FRAX; Guideline
Categories
Funding
- Servier
- Consilient Health
- Amgen/GSK
- Shire
- Eli Lilly
- Amgen
- GSK
- MSD
- Novartis
- Proctor Gamble
- ProStrakan
- Roche
- Medtronic
- Tethys
- GE Lunar
- Bayer
- Hologic
- Lilly
- Merck
- Pfizer
- Warner-Chilcott
- Innovus 3i
- Alliance for Better Bone Health
- Biointetica
- Celtrix
- D3A
- General Electric
- Kissel
- Medimaps
- Merck Research Labs
- Sanofi-Aventis
- UBS
- Olympus
- Synthes
- Stryker
- Biomet
- Medical Research Council [MR/K006312/1] Funding Source: researchfish
- MRC [MR/K006312/1] Funding Source: UKRI
Ask authors/readers for more resources
Since the launch in 2008 by the National Osteoporosis Guideline Group (NOGG), of guidance for the diagnosis and management of osteoporosis in postmenopausal women and older men in the UK there have been significant advances in risk assessment and treatment. These have been incorporated into an updated version of the guideline, with an additional focus on the management of glucocorticoid-induced osteoporosis, the role of calcium and vitamin D therapy and the benefits and risks of long-term bisphosphonate therapy. The updated guideline is summarised below. The recommendations in the guideline are intended to aid management decisions but do not replace the need for clinical judgement in the care of individuals in clinical practice. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available